Clinical Trial Update: Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the investigational drug A6 for chronic lymphocytic leukemia and small lymphocytic lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• A6

Snippet

Sponsor: Ångstrom Pharmaceuticals | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Status: TERMINATED